Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
- Published In:
- Lancet (London, England), 386(9999), 1147-55 (2015)
- Authors:
- Leder, Benjamin Z, Tsai, Joy N, Uihlein, Alexander V, Wallace, Paul M, Lee, Hang, Neer, Robert M, Burnett-Bowie, Sherri-Ann M
- Database ID:
- RPEP-02701
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-02701APA
Leder, Benjamin Z; Tsai, Joy N; Uihlein, Alexander V; Wallace, Paul M; Lee, Hang; Neer, Robert M; Burnett-Bowie, Sherri-Ann M. (2015). Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.. Lancet (London, England), 386(9999), 1147-55. https://doi.org/10.1016/S0140-6736(15)61120-5
MLA
Leder, Benjamin Z, et al. "Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.." Lancet (London, 2015. https://doi.org/10.1016/S0140-6736(15)61120-5
RethinkPeptides
RethinkPeptides Research Database. "Denosumab and teriparatide transitions in postmenopausal ost..." RPEP-02701. Retrieved from https://rethinkpeptides.com/research/leder-2015-denosumab-and-teriparatide-transitions
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.